The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

In a report released today, Matthew Weston from UBS downgraded Novartis AG (NOVN – Research Report) to a Hold, with a price target of ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...